Inhibrx (INBX) Stock Price, News & Analysis

+0.29 (+0.85%)
(As of 01:56 PM ET)
Today's Range
50-Day Range
52-Week Range
106,131 shs
Average Volume
682,059 shs
Market Capitalization
$1.63 billion
P/E Ratio
Dividend Yield
Price Target

Inhibrx MarketRank™ Stock Analysis

Analyst Rating
2.00 Rating Score
21.5% Downside
$27.00 Price Target
Short Interest
6.04% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.85 out of 5 stars

Medical Sector

595th out of 910 stocks

Biological Products, Except Diagnostic Industry

101st out of 153 stocks

INBX stock logo

About Inhibrx Stock (NASDAQ:INBX)

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

INBX Stock Price History

INBX Stock News Headlines

INBX Apr 2024 50.000 put
One trade. One ticker. One week.
Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week?
INBX Apr 2024 55.000 call
Inhibrx just downgraded at Jefferies, here's why
One trade. One ticker. One week.
Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week?
Inhibrx just downgraded at LifeSci Capital, here's why
Inhibrx Inc Ordinary Shares INBX
Inhibrx Inc Ordinary Shares
Inhibrx posts Q3 results
See More Headlines
Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$1.80 million
Book Value
$0.92 per share


Free Float
Market Cap
$1.62 billion
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

INBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Inhibrx stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INBX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INBX, but not buy additional shares or sell existing shares.
View INBX analyst ratings
or view top-rated stocks.

What is Inhibrx's stock price target for 2024?

2 brokers have issued 12 month price targets for Inhibrx's stock. Their INBX share price targets range from $27.00 to $27.00. On average, they expect the company's stock price to reach $27.00 in the next year. This suggests that the stock has a possible downside of 21.5%.
View analysts price targets for INBX
or view top-rated stocks among Wall Street analysts.

How have INBX shares performed in 2024?

Inhibrx's stock was trading at $38.00 at the beginning of 2024. Since then, INBX stock has decreased by 9.5% and is now trading at $34.38.
View the best growth stocks for 2024 here

Are investors shorting Inhibrx?

Inhibrx saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,150,000 shares, an increase of 34.4% from the March 15th total of 1,600,000 shares. Based on an average daily trading volume, of 726,500 shares, the days-to-cover ratio is currently 3.0 days. Approximately 6.0% of the company's shares are sold short.
View Inhibrx's Short Interest

When is Inhibrx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our INBX earnings forecast

How were Inhibrx's earnings last quarter?

Inhibrx, Inc. (NASDAQ:INBX) announced its earnings results on Wednesday, February, 28th. The company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.07) by $0.66. The company had revenue of $1.63 million for the quarter, compared to analysts' expectations of $0.10 million. Inhibrx had a negative net margin of 13,408.95% and a negative trailing twelve-month return on equity of 590.78%.

What other stocks do shareholders of Inhibrx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU).

When did Inhibrx IPO?

Inhibrx (INBX) raised $102 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are Inhibrx's major shareholders?

Inhibrx's stock is owned by a variety of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.06%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe.
View institutional ownership trends

How do I buy shares of Inhibrx?

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INBX) was last updated on 4/23/2024 by Staff

From Our Partners